These innovations allowed us to show that gluten peptide-stimulated whole blood IL-2 and IFN-γ release, and CD4+ T cell proliferation were significantly reduced in CD patients during treatment with Nexvax2 peptide immunotherapy, but not in placebo-treated CD patients. Here, IL2 is linked to Cowden disease.